{
    "nct_id": "NCT04898634",
    "official_title": "A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer",
    "inclusion_criteria": "* Confirmed adenocarcinoma of the prostate which has spread to other body parts\n* Part 1: Prior treatment with at least 1 prior novel androgen receptor (AR)-targeted therapy or chemotherapy\n* Measurable or evaluable disease\n* Concurrent use of any other anticancer treatment must be discontinued for at least 2 weeks before the first dose of study drug\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Prior surgical removal of testicles; or, for participants who have not undergone surgical removal of testicles, must be receiving ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone analog\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Disease conditions\n\n* Active central nervous system (CNS) involvement\n* Toxicity related to prior anticancer therapy has not adequately recovered\n\nPrior/Concomitant Therapy\n\n* Prior treatment with human kallikrein (KLK) 2-targeted therapy\n* Received, or are receiving, medications that suppress the immune system within 3 days prior to the first dose of study drug\n* Received or plans to receive any live, attenuated vaccine within 4 weeks prior to the first dose of study drug\n\nPrior/Concurrent Medical Conditions\n\n* Diagnosis of cancer other than prostate cancer within 2 years prior to the first dose of study drug\n* Solid organ or bone marrow transplantation\n* Major clotting diseases within one month prior to the first dose of study drug\n* Active autoimmune disease within 12 months prior to the first dose of study drug\n* Active infection\n* Major diseases of heart and blood vessels within 6 months prior to the first dose of study drug\n* Clinically significant lung diseases\n* Active or chronic hepatitis B or hepatitis C infection\n* Known positive test result for human immunodeficiency virus (unless stable on antiretroviral therapy with undetectable viral load)\n* Any serious underlying medical conditions or other issue that would impair the ability of the participant to receive or tolerate the planned treatment",
    "miscellaneous_criteria": ""
}